Abstract 2974
Background
The EGFR tyrosine kinase inhibitor (TKI) gefitinib (IRESSATM) received approval in France on 4 Nov 2009. At the French authority's request, the EPIDAURE study was initiated in Jan 2012 to explore real-life gefitinib use in terms of patients (pts) population, EGFR mutation testing and efficacy.
Methods
Eligible French pts had NSCLC of any stage, histology or treatment line, and started gefitinib treatment between Jan 2011-Mar 2013 prior to study entry (‘prevalent pts’) or at study entry (‘incident pts’). Efficacy, safety and quality of life with gefitinib were assessed over a 2-year follow-up period (previously reported: ELCC 2016 #327). Efficacy data (objective response rate [ORR], progression-free survival [PFS], overall survival [OS]) in pts with EGFR common mutation-positive NSCLC who received 1st line gefitinib are presented by mutation subtype.
Results
Of 361 pts recruited across 104 sites in France (116 incident pts), 283 were EGFR mutation-positive and received 1st line gefitinib (94 incident pts); EGFR mutation subtypes data were available for 260 (82 incident pts). Median duration of follow-up: 20.8 months. In the total 1st line population: median age was 71 years, 61% were never-smokers, 73% had performance status 0-1 and 33% had brain metastases. ORR was 68.5% (95% CI 61.9, 72.9), median PFS was 11.5 months (95% CI 10.0, 13.4) and median OS from initiation of gefitinib was 25.7 months (95% CI 23.4, 27.9). Better outcomes were observed with exon 19 Del vs L858R mutations (Table), especially in incident pts.
Conclusions
EPIDAURE provided a large cohort of French pts with EGFR mutation-positive NSCLC treated with 1st line gefitinib. Higher ORR and prolonged OS/PFS in exon 19 Del vs L858R mutations indicate that this subtype represents distinct tumours which may be more sensitive to EGFR TKI therapy. Findings were similar to afatinib data in Caucasian pts. Funding AstraZeneca.
| Incident pts (n = 82) | Total pts (n = 260) | |||
|---|---|---|---|---|
| Exon 19 del | L858R | Exon 19 del | L858R | |
| EGFR mutation subtype, n (%) | 49 (60) | 29 (35) | 136 (52) | 106 (41) |
| ORR, n (%) (95% CI) | 39 (83) (72.3, 93.7) | 16 (59) (40.8, 77.8) | 102 (78) (70.8, 85.0) | 66 (64) (54.8, 73.4) |
| PFS, median months (95% CI) | 12.2 (9.1, 18.1) | 6.4 (5.3, 10.5) | 12.8 (10.2, 14.9) | 11.0 (7.7, 13.4) |
| OS, median months (95% CI) | 27.2 (24.0, NC) | 18.1 (10.9, 26.4) | 31.4 (25.6, 34.6) | 19.6 (16.9, 24.2) |
CI, confidence interval; EGFR, epidermal growth factor receptor; NC, non-calculable; OS, overall survival; PFS, progression-free survival
Clinical trial identification
Legal entity responsible for the study
AstraZeneca
Funding
AstraZeneca
Disclosure
M. Perol, J-F. Morère, J. Cadranel: Honoraria received from Astra Zeneca (Advisory Board) M. Licour: Employee of AstraZeneca. All other authors have declared no conflicts of interest.